Negative influence of changing biopsy practice patterns on the predictive value of prostate-specific antigen for cancer detection on prostate biopsy

Cancer

Volumn 112, Issue 8, 2008, Pages 1718-1725

  Schwartz, Michael J ^a   Hwang, David H ^a   Hung, Andrew J ^a   Han, Jullet ^a   McClain, Justin W ^a   Shemtov, M Mendel ^a   Te, Alexis E ^a   Sosa, R Ernest ^a   Vaughan Jr , E Darracott ^a   Scherr, Douglas S ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

Biopsy practice patterns; Detection; Digital rectal examination; Prostate cancer; Prostate specific antigen; Transrectal ultrasound

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BIOPSY TECHNIQUE; CANCER DIAGNOSIS; DATA ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FALSE POSITIVE RESULT; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INFORMATION PROCESSING; INTERMETHOD COMPARISON; MALE; MULTIVARIATE ANALYSIS; PREDICTOR VARIABLE; PREVALENCE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; STATISTICAL ANALYSIS; UNITED STATES; VALIDATION PROCESS;

BIOPSY; COHORT STUDIES; DIGITAL RECTAL EXAMINATION; HUMANS; MALE; MIDDLE AGED; ORGAN SIZE; PHYSICIAN'S PRACTICE PATTERNS; PREDICTIVE VALUE OF TESTS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 42149123289     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23353     Document Type: Article

References (22)

1. Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991;324:1156-1161. Erratum in: N Engl J Med. 1991;325:1324.
2. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA. 1993;270:948-954.
3. Cooner WH, Mosley BR, Rutherford CL Jr, et al. Prostate cancer detection in a clinical urology practice by ultrasonography, digital rectal exam, and prostate specific antigen. J Urol. 1990;143:1146-1152.
4. Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol. 1994;151:1283-1290.
5. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 2004;350:2239-2246. Erratum in: N Engl J Med. 2004;351:1470.
6. Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst. 2003;95:868-878.
7. Cooperberg MR, Lubeck DP, Mehta SS, Caroll PR;CaPSURE. Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol. 2003;170(6 pt 2):S21-S25; discussion S26-S27. Erratum in: J Urol. 2004;171(2 pt 1):811.
8. Roberts RO, Bergstralh EJ, Peterson NR, Bostwick DG, Lieber MM, Jacobsen SJ. Positive and negative biopsies in the pre-prostate specific antigen and prostate specific antigen eras, 1980 to 1997. J Urol. 2000;163:1471-1475.
9. Master VA, Chi T, Simko JP, Weinberg V, Carroll PR. The independent impact of extended pattern biopsy on prostate cancer stage migration. J Urol. 2005;174:1789-1793.
10. Albertsen PC, Hanley JA, Barrows GH, et al. Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst. 2005;97:1248-1253.
11. Sengupta S, Slezak JM, Blute ML, et al. Trends in distribution and prognostic significance of Gleason grades on radical retropubic prostatectomy specimens between 1989 and 2001. Cancer. 2006;106:2630-2635.
12. Sakr WA, Grignon DJ, Haas GP, Heilbrun LK, Pontes JE, Crissman JD. Age and racial distribution of prostatic intraepithelial neoplasia. Eur Urol. 1996;30:138-144.
13. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66.
14. Djavan B, Ravery V, Zlotta A, et al. Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? J Urol. 2001;166:1679-1683.
15. Borden LS Jr, Wright JL, Kim J, Latchamsetty K, Porter CR. An abnormal digital rectal examination is an independent predictor of Gleason > or =7 prostate cancer in men undergoing initial prostate biopsy: a prospective study of 790 men. BJU Int. 2007;99:559-563.
16. Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, Downs J. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol. 2004;172(4 pt 1):1297-1301.
17. Kobayashi T, Mitsumori K, Kawahara T, Nishizawa K, Ogura K, Ide Y. Prostate gland volume is a strong predictor of biopsy results in men 70 years or older with prostate-specific antigen levels of 2.0-10.0 ng/mL. Int J Urol. 2005;12:969-975.
18. Eskicorapci SY, Guliyev F, Akdogan B, Dogan HS, Ergen A, Ozen H. Individualization of the biopsy protocol according to prostate gland volume for prostate cancer detection. J Urol. 2005;173:1536-1540.
19. Orozco R, Kunnel B, O'Dowd GJ, Stamey TA. Positive prostate biopsy rate consistently increases with age at the same prostate-specific antigen level in patients with normal digital rectal examination. Urology. 1998;51:531-533.
20. Carswell BM, Woda BA, Wang X, Li C, Dresser K, Jiang Z. Detection of prostate cancer by alpha-methylacyl CoA racemase (P504S) in needle biopsy specimens previously reported as negative for malignancy. Histopathology. 2006;48:668-673.
21. Browne TJ, Hirsch MS, Brodsky G, Welch WR, Loda MF, Rubin MA. Prospective evaluation of AMACR (P504S) and basal cell markers in the assessment of routine prostate needle biopsy specimens. Hum Pathol. 2004;35:1462-1468.
22. van der Cruijsen-Koeter IW, Vis AN, Roobol MJ, et al. Comparison of screen detected and clinically diagnosed prostate cancer in the European randomized study of screening for prostate cancer, section Rotterdam. J Urol. 2005;174:121-125.